396 related articles for article (PubMed ID: 31215680)
1. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.
Dotan I; Allez M; Danese S; Keir M; Tole S; McBride J
Med Res Rev; 2020 Jan; 40(1):245-262. PubMed ID: 31215680
[TBL] [Abstract][Full Text] [Related]
2. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
3. [New molecules in the treatment of inflammatory bowel disease].
Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
[TBL] [Abstract][Full Text] [Related]
4. Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
Bravatà I; Allocca M; Fiorino G; Danese S
Curr Opin Pharmacol; 2015 Dec; 25():67-71. PubMed ID: 26687159
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns.
Yacyshyn BR; Lazarovits A; Tsai V; Matejko K
Gastroenterology; 1994 Nov; 107(5):1364-71. PubMed ID: 7523224
[TBL] [Abstract][Full Text] [Related]
6. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
7. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
8. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
10. Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases.
Evans-Marin HL; Cong Y
Inflamm Allergy Drug Targets; 2015; 14(1):4-12. PubMed ID: 26296210
[TBL] [Abstract][Full Text] [Related]
11. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
12. Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.
Corbo C; Cromer WE; Molinaro R; Toledano Furman NE; Hartman KA; De Rosa E; Boada C; Wang X; Zawieja DC; Agostini M; Salvatore F; Abraham BP; Tasciotti E
Nanoscale; 2017 Oct; 9(38):14581-14591. PubMed ID: 28932838
[TBL] [Abstract][Full Text] [Related]
13. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
14. Targeting integrins and adhesion molecules to combat inflammatory bowel disease.
Marafini I; Sedda S; Pallone F; Monteleone G
Inflamm Bowel Dis; 2014 Oct; 20(10):1885-9. PubMed ID: 25215614
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
16. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
17. The Multiple Faces of Integrin-ECM Interactions in Inflammatory Bowel Disease.
Garlatti V; Lovisa S; Danese S; Vetrano S
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638778
[TBL] [Abstract][Full Text] [Related]
18. Emerging immunological targets in inflammatory bowel disease.
Monteleone G; Pallone F; MacDonald TT
Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
[TBL] [Abstract][Full Text] [Related]
19. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation.
Meenan J; Spaans J; Grool TA; Pals ST; Tytgat GN; van Deventer SJ
Gut; 1997 Feb; 40(2):241-6. PubMed ID: 9071939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
